IL17A and hepatocellular carcinoma: In HCC, tumor-derived type 3 innate lymphoid cells (ILC3s) promote hepatic stellate cell (HSC) activation via an IL-17A-dependent pathway, driving liver fibrosis, which is associated with poor patient prognosis 62,63.